Evidence map›Paper›PMID 32253454›Full record

Trial reportAnnals of hematology2020

Separase activity distribution can be a marker of major molecular response and proliferation of CD34

Birgit Spiess, Helga Kleiner, Johanna Flach, Alice Fabarius, Susanne Saussele, Wolf-Karsten Hofmann, Wolfgang Seifarth

Open access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Separase and Roads to Disengage Sister Chromatids during Anaphase.International journal of molecular sciences · 2023
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Birgit SpiessDepartment of Hematology and Oncology, University Hospital Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. birgit.spiess@medma.uni-heidelberg.de.
Helga KleinerDepartment of Hematology and Oncology, University Hospital Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Johanna FlachDepartment of Hematology and Oncology, University Hospital Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Alice FabariusDepartment of Hematology and Oncology, University Hospital Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Susanne SausseleDepartment of Hematology and Oncology, University Hospital Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Wolf-Karsten HofmannDepartment of Hematology and Oncology, University Hospital Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Wolfgang SeifarthDepartment of Hematology and Oncology, University Hospital Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
University Hospital Heidelberg · DEUniversity Medical Centre Mannheim · DEHeidelberg University · DE

Funding

José Carreras Leukämie-Stiftung DJCLS R 14/11 and 13R/2017
6 · The paper itself

Abstract

Separase, a cysteine endopeptidase, is a key player in mitotic sister chromatid separation, replication fork dynamics, and DNA repair. Aberrant expression and/or altered separase proteolytic activity are associated with aneuploidy, tumorigenesis, and disease progression. Since genomic instability and clonal evolution are hallmarks of progressing chronic myeloid leukemia (CML), we have comparatively examined separase proteolytic activity in TKI-treated chronic phase CML. Separase proteolytic activity was analyzed on single cell level in 88 clinical samples and in 14 healthy controls by a flow cytometric assay. In parallel, BCR-ABL1 gene expression and replication fork velocity were measured by qRT-PCR and DNA fiber assays, respectively. The separase activity distribution (SAD) value indicating the occurrence of MNCs with elevated separase proteolytic activity within samples was found to positively correlate with BCR-ABL1 gene expression levels and loss of MMR (relapse) throughout routine BCR-ABL1 monitoring. Analyses of CD34

Indexed as

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveAdolescentAdultAgedAged, 80 and overAntigens, CD34Biomarkers, TumorCell ProliferationFemaleFusion Proteins, bcr-ablHumansMaleMiddle AgedProtein Kinase InhibitorsSeparaseAntigens, CD34BCR-ABL1 fusion protein, humanBiomarkers, TumorESPL1 protein, humanFusion Proteins, bcr-ablProtein Kinase InhibitorsSeparaseBCR-ABL1 expressionChronic myeloid leukemia (CML)ESPL1/separaseLeukemic nicheLeukemic stem cell (LSC)Major molecular remission (MMR)

Identifiers

PMID32253454
PMCPMC7196950
OpenAlexW3014795974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.